Coverage
-
February 04, 2016
Astellas Pharma agreed Thursday to pay indirect purchasers of its Prograf $13.25 million to settle claims that it delayed generic competition to the immunosuppressant drug amid an appeal of class certification in the antitrust case.
9 other articles on this case.
View all »